Table 4.

Crude HR for bleomycin sensitivity using cancer and aneuploidy end points stratified by tumor-suppressor mutation and LOH status

Cancer
Aneuploidy
EventsnCrude HR (95% CI)PEventsnCrude HR (95% CI)P
17p het
    ≤0.63681.0*3611.0*
    >0.65801.33 (0.32-5.57)0.709672.61 (0.71-9.65)0.15
17p LOH
    ≤0.66191.0*2101.0*
    >0.611142.69 (0.99-7.31)0.053558.79 (1.68-46.1)0.01
9p het
    ≤0.63301.0*1251.0*
    >0.62370.39 (0.07-2.37)0.314332.92 (0.33-26.1)0.34
9p LOH
    ≤0.66581.0*4471.0*
    >0.614582.30 (0.88-5.99)0.0911393.64 (1.15-11.5)0.03
TP53 wt
    ≤0.64711.0*5651.0*
    >0.610842.00 (0.63-6.38)0.2412692.16 (0.76-6.14)0.15
TP53 mut
    ≤0.65151.0*061.0*
    >0.66102.18 (0.66-7.18)0.2023
p16 wt
    ≤0.67731.0*6621.0*
    >0.612761.50 (0.59-3.80)0.4013602.21 (0.84-5.83)0.11
p16 mut
    ≤0.63131.0*0101.0*
    >0.63161.28 (0.21-7.65)0.79212
  • NOTE: Bleomycin sensitivity is defined as having >0.6 breaks per cell.

  • * Reference group.